Andrew M. Evens

I am thrilled to be a member of the Rutgers Cancer Institute of New Jersey as the Deputy Director for Clinical Services; System Director of Medical Oncology and Oncology Lead for the Combined Medical Group with RWJBarnabas Health (RWJBH); and Associate Vice Chancellor for Clinical Innovation and Data Analytics, within Rutgers Health at Rutgers University. Rutgers Cancer Institute is one of only 56 cancer centers recognized nationally and New Jersey’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center. Our mission is to deliver comprehensive and compassionate cancer care across the health system with access to worldwide expertise and innovative cancer therapies not available elsewhere in the state.

I completed a fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where I also remained as a faculty member altogether for 11 years. Most recently, I served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine.

My clinical expertise and research interests are focused in the field of lymphoid malignancies, in particular Hodgkin lymphoma and non-Hodgkin lymphoma. Over the past 20 years, I have been the principal investigator of more than 100 cancer clinical trials that have included phase I, II, and III studies, and I help lead several national and global health outcomes and data analytics projects in lymphoma. Collectively, my research has been continuously funded by the National Institutes of Health (NIH) since 2005. This has resulted in 400+ research abstract presentations at national and international cancer symposiums, 230+ manuscripts in peer-reviewed publications, and 40+ book chapters with an emphasis on the prognosis, treatment, and health outcomes of cancer.

Nationally, I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee, and an ad hoc member of additional clinical and scientific committees for the NIH, Cancer Therapy Evaluation Program (CTEP), and the Food and Drug Administration (FDA). I was an associate editor for the British Journal of Haematology for 8 years and now serve as the inaugural editor-in-chief of the gold open-access journal, eJHaem. I am Vice-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group; Co-Chair of the Big 10 Cancer Research Consortium lymphoma working group; and a re-elected member and the Chair-elect for the esteemed North American Scientific Advisory Board (SAB) for the Lymphoma Research Foundation that is comprised of 45 world-renowned lymphoma experts. Finally, I help lead a multitude of regional, national, and international educational forums and scientific events.

Rutgers Cancer Institute has a rich history of conducting state-of-the-art and groundbreaking cancer research, and together with RWJBH and Rutgers Health, offers international expertise, multidisciplinary clinical care, leading-edge cancer treatments, and unparalleled resources for cancer patients and their families all close to home. I am honored to be a member of the Rutgers Cancer Institute and a leader of the RWJBH oncology service line working alongside the multitude of outstanding oncology providers providing compassionate and expert cancer care throughout the state of New Jersey and beyond.